McKinsey Projects U.S. Healthcare EBITDA to Reach $500B+ as Margin Pressures Shift Across Payers and Providers
What You Should Know
- A new report from McKinsey & Company, the 2027 U.S. healthcare outlook, finds that healthcare services and technology (HST) is emerging as the industry’s fastest-growing value pool segment, with AI accelerating a shift in how companies generate revenue.
- U.S. healthcare economics have experienced a historic structural reset: total provider EBITDA dropped to $241 billion in 2022 before rebounding to 350–369 billion in 2025, while total payer EBITDA collapsed from $60 billion in 2022 to just $9 billion in 2025 (turning collective risk-bearing businesses negative to $4 billion in 2025 for the first time this decade).
- The 2026 U.S. federal budget deficit is forecast at $1.9 trillion (5.8% of GDP) and national debt has crossed $40 trillion, constraining federal fiscal flexibility even as healthcare delivery productivity declined ~1% annually from 2019 to 2025.
- Overall healthcare EBITDA is projected to grow at a 7% CAGR from 2025 to 2030, decelerating to 4% annually through 2027 due to ACA subsidy expirations and Medicaid disenrollment before accelerating to 9% annually between 2027 and 2030.
The Capital Shift: Software Platforms and Data Ingestion vs. Legacy BPO Displacement
The expansion within HST is characterized by a stark operational divide between software-driven automation and legacy business process outsourcing (BPO):
- Data, Analytics, and Cloud Infrastructure: Enterprise data and analytics platforms represent the fastest-growing subsegment, charting more than 11% annual revenue gains, followed closely by core software platforms at greater than 10%. Over the next five years, generative and agentic AI adoption is projected to add one to four percentage points of incremental top-line revenue growth annually to these categories as health systems and payers outsource complex engineering to external specialists. Concurrently, AI-driven reductions in software development lifecycles and administrative overhead will accelerate software EBITDA growth by an additional one to three percentage points each year.
- The Erosion of Headcount-Based Labor Arbitrage: In contrast, legacy administrative services—where commercial contracts have historically been priced on physical headcount, FTE billable hours, and raw transaction volumes—face rapid obsolescence. As health plans and hospital business offices adopt internal AI tools to automate basic claims processing, customer service triage, and billing reconciliation, payers are demanding that outsourced vendors pass through the cost savings generated by automated delivery. Consequently, traditional administrative BPO revenue growth is projected to decelerate by two to three percentage points annually, leaving legacy service lines flat or contracting through 2030.
- Upstream Payment Integrity: AI is transforming healthcare payment integrity from retrospective audit and recovery toward prepayment prevention. Instead of billing departments and commercial payers paying recovery contractors contingency fees to claw back inappropriate claims months after payment, machine learning models embedded directly into core claims engines and provider electronic health records resolve billing and coding discrepancies before an electronic claim is ever generated.
The Productivity Imperative: Moving from Scribe Pilots to Measured Enterprise ROI
Healthcare delivery has historically suffered from structural productivity stagnation: real gross output per full-time equivalent employee in healthcare delivery fell approximately 1% between 1998 and 2023, while output per employee across all non-healthcare service industries advanced 56%. However, production-grade artificial intelligence is beginning to break this historical plateau, shifting enterprise focus from discrete pilots to structured financial returns:
- Ambient Documentation at Institutional Scale: The first wave of deployment has proven economic and operational viability in high-friction clinical workflows. In one of the largest published clinical deployments, ambient documentation utilized by 7,260 physicians across roughly 2.6 million patient visits recovered an estimated 15,791 hours of documentation time relative to non-users, returning the equivalent of 1,794 working days directly to direct patient care and personal bandwidth.
- The ROI Distribution Reality: While 92% of surveyed healthcare enterprise decision-makers report they have either implemented generative AI or are actively running proofs of concept, realization of financial value remains in an early transition. Among organizations with live implementations, 38% report a measurable positive ROI (14% achieving less than a twofold return, 20% capturing a two- to fourfold return, and 4% generating greater than a fourfold return). An additional 38% state their deployments are tracking toward positive financial returns but have not yet formally quantified outcomes, while 24% have yet to measure positive returns.
- The Rise of Autonomous Multi-Agent Systems: Demonstrating the movement from isolated conversational chatbots toward complex workflow orchestration, 74% of healthcare leaders report implementing or pursuing proofs of concept for multi-agent workflows. These multi-agent architectures deploy cooperating software agents designed to ingest clinical context, retrieve medical necessity guidelines, query legacy EHR databases, and execute multi-step operational chains across care coordination, prior authorization, and patient scheduling without human intervention between individual steps.
The Strategic Tailwind: The “Buy and Partner” Procurement Dominance
A primary operational driver underpinning the HST sector’s $120+ billion EBITDA projection is the decision by health system and payer executive leadership to abandon proprietary, in-house software development in favor of third-party commercial platforms:
Faced with constrained capital budgets, severe competition for machine learning engineering talent, and strict liability around clinical model safety, 74% of healthcare organizations plan to source their AI capabilities externally—with 48% relying on strategic vendor partnerships and 26% buying commercial software outright. Only 26% of organizations intend to build AI models and infrastructure in-house.
This procurement consensus establishes a sustained commercial tailwind for specialized technology vendors capable of providing pre-built electronic health record connectors, verifiable evidence citation frameworks, HIPAA-compliant model governance, and active change management at scale.
Sector-Wide Context: Payer Troughs, Provider Pressures, and Capital Reallocation
The expansion of the HST sector occurs against severe margin pressures across traditional healthcare risk-bearing and delivery verticals:
- Payer Margin Reset: Total health plan EBITDA collapsed from $62 billion in 2023 to $33 billion in 2024, reaching a trough of $9 billion in 2025, as medical-cost inflation outpaced premium rate adjustments. Major risk-bearing lines collectively generated negative EBITDA (-$4 billion) in 2025. While commercial premium increases (9% to 12% in 2026) and improved Medicare Advantage payment updates (5.06% in 2026) are driving an inflection point, adverse risk selection from ACA subsidy expirations (causing an estimated 8.5 to 9.0 million cumulative enrollment drop through 2027) and Medicaid redeterminations (projected loss of 7 to 9 million lives by 2028) will keep underwriting margins suppressed through 2027. Payer EBITDA is projected to rebuild to $84.5 billion by 2030, supported by lower-risk administrative-services-only (ASO) and stop-loss products.
- Provider Site-of-Care Migration: Provider EBITDA recovered from $241 billion in 2022 to $369 billion in 2025 (a 10.5% margin), but faces renewed compression through 2027 due to uncompensated care spikes from Medicaid and ACA coverage losses. Long-term hospital margins are projected to stabilize near 8.8%, but acute hospitals’ share of the total provider profit pool will decline from 42% in 2019 to 39% by 2030. Capital is shifting aggressively to lower-cost outpatient settings: Ambulatory Surgery Center (ASC) EBITDA is forecast to grow at 6.7% annually (reaching 23.1% margins by 2030), compared to 3.7% annual growth for acute hospitals, driven by CMS expansion of the ASC Covered Procedures List and commercial payer site-of-care steerage.
- Pharmacy Supply Chain Re-Engineering: Total pharmacy value chain EBITDA is projected to expand from $97 billion in 2025 to $138 billion by 2030 (a 7% CAGR), with specialty pharmacy and clinical infusion capturing roughly half the pool. Hospital-owned specialty pharmacy represents the fastest-growing delivery segment, expanding at 15% annually. Simultaneously, legislative mandates—including PBM transparency provisions under the Consolidated Appropriations Act of 2026, successive Medicare drug price negotiations, and a revised 340B retrospective rebate pilot scheduled for 2027—are dismantling traditional hidden drug spreads and retrospective rebates in favor of transparent, fee-for-service administrative models.
What You Should Know
- A new report from McKinsey & Company, the 2027 U.S. healthcare outlook, finds that healthcare services and technology (HST) is emerging as the industry’s fastest-growing value pool segment, with AI accelerating a shift in how companies generate revenue.
- U.S. healthcare economics have experienced a historic structural reset: total provider EBITDA dropped to $241 billion in 2022 before rebounding to 350–369 billion in 2025, while total payer EBITDA collapsed from $60 billion in 2022 to just $9 billion in 2025 (turning collective risk-bearing businesses negative to $4 billion in 2025 for the first time this decade).
- The 2026 U.S. federal budget deficit is forecast at $1.9 trillion (5.8% of GDP) and national debt has crossed $40 trillion, constraining federal fiscal flexibility even as healthcare delivery productivity declined ~1% annually from 2019 to 2025.
- Overall healthcare EBITDA is projected to grow at a 7% CAGR from 2025 to 2030, decelerating to 4% annually through 2027 due to ACA subsidy expirations and Medicaid disenrollment before accelerating to 9% annually between 2027 and 2030.
The Capital Shift: Software Platforms and Data Ingestion vs. Legacy BPO Displacement
The expansion within HST is characterized by a stark operational divide between software-driven automation and legacy business process outsourcing (BPO):
- Data, Analytics, and Cloud Infrastructure: Enterprise data and analytics platforms represent the fastest-growing subsegment, charting more than 11% annual revenue gains, followed closely by core software platforms at greater than 10%. Over the next five years, generative and agentic AI adoption is projected to add one to four percentage points of incremental top-line revenue growth annually to these categories as health systems and payers outsource complex engineering to external specialists. Concurrently, AI-driven reductions in software development lifecycles and administrative overhead will accelerate software EBITDA growth by an additional one to three percentage points each year.
- The Erosion of Headcount-Based Labor Arbitrage: In contrast, legacy administrative services—where commercial contracts have historically been priced on physical headcount, FTE billable hours, and raw transaction volumes—face rapid obsolescence. As health plans and hospital business offices adopt internal AI tools to automate basic claims processing, customer service triage, and billing reconciliation, payers are demanding that outsourced vendors pass through the cost savings generated by automated delivery. Consequently, traditional administrative BPO revenue growth is projected to decelerate by two to three percentage points annually, leaving legacy service lines flat or contracting through 2030.
- Upstream Payment Integrity: AI is transforming healthcare payment integrity from retrospective audit and recovery toward prepayment prevention. Instead of billing departments and commercial payers paying recovery contractors contingency fees to claw back inappropriate claims months after payment, machine learning models embedded directly into core claims engines and provider electronic health records resolve billing and coding discrepancies before an electronic claim is ever generated.
The Productivity Imperative: Moving from Scribe Pilots to Measured Enterprise ROI
Healthcare delivery has historically suffered from structural productivity stagnation: real gross output per full-time equivalent employee in healthcare delivery fell approximately 1% between 1998 and 2023, while output per employee across all non-healthcare service industries advanced 56%. However, production-grade artificial intelligence is beginning to break this historical plateau, shifting enterprise focus from discrete pilots to structured financial returns:
- Ambient Documentation at Institutional Scale: The first wave of deployment has proven economic and operational viability in high-friction clinical workflows. In one of the largest published clinical deployments, ambient documentation utilized by 7,260 physicians across roughly 2.6 million patient visits recovered an estimated 15,791 hours of documentation time relative to non-users, returning the equivalent of 1,794 working days directly to direct patient care and personal bandwidth.
- The ROI Distribution Reality: While 92% of surveyed healthcare enterprise decision-makers report they have either implemented generative AI or are actively running proofs of concept, realization of financial value remains in an early transition. Among organizations with live implementations, 38% report a measurable positive ROI (14% achieving less than a twofold return, 20% capturing a two- to fourfold return, and 4% generating greater than a fourfold return). An additional 38% state their deployments are tracking toward positive financial returns but have not yet formally quantified outcomes, while 24% have yet to measure positive returns.
- The Rise of Autonomous Multi-Agent Systems: Demonstrating the movement from isolated conversational chatbots toward complex workflow orchestration, 74% of healthcare leaders report implementing or pursuing proofs of concept for multi-agent workflows. These multi-agent architectures deploy cooperating software agents designed to ingest clinical context, retrieve medical necessity guidelines, query legacy EHR databases, and execute multi-step operational chains across care coordination, prior authorization, and patient scheduling without human intervention between individual steps.
The Strategic Tailwind: The “Buy and Partner” Procurement Dominance
A primary operational driver underpinning the HST sector’s $120+ billion EBITDA projection is the decision by health system and payer executive leadership to abandon proprietary, in-house software development in favor of third-party commercial platforms:
Faced with constrained capital budgets, severe competition for machine learning engineering talent, and strict liability around clinical model safety, 74% of healthcare organizations plan to source their AI capabilities externally—with 48% relying on strategic vendor partnerships and 26% buying commercial software outright. Only 26% of organizations intend to build AI models and infrastructure in-house.
This procurement consensus establishes a sustained commercial tailwind for specialized technology vendors capable of providing pre-built electronic health record connectors, verifiable evidence citation frameworks, HIPAA-compliant model governance, and active change management at scale.
Sector-Wide Context: Payer Troughs, Provider Pressures, and Capital Reallocation
The expansion of the HST sector occurs against severe margin pressures across traditional healthcare risk-bearing and delivery verticals:
- Payer Margin Reset: Total health plan EBITDA collapsed from $62 billion in 2023 to $33 billion in 2024, reaching a trough of $9 billion in 2025, as medical-cost inflation outpaced premium rate adjustments. Major risk-bearing lines collectively generated negative EBITDA (-$4 billion) in 2025. While commercial premium increases (9% to 12% in 2026) and improved Medicare Advantage payment updates (5.06% in 2026) are driving an inflection point, adverse risk selection from ACA subsidy expirations (causing an estimated 8.5 to 9.0 million cumulative enrollment drop through 2027) and Medicaid redeterminations (projected loss of 7 to 9 million lives by 2028) will keep underwriting margins suppressed through 2027. Payer EBITDA is projected to rebuild to $84.5 billion by 2030, supported by lower-risk administrative-services-only (ASO) and stop-loss products.
- Provider Site-of-Care Migration: Provider EBITDA recovered from $241 billion in 2022 to $369 billion in 2025 (a 10.5% margin), but faces renewed compression through 2027 due to uncompensated care spikes from Medicaid and ACA coverage losses. Long-term hospital margins are projected to stabilize near 8.8%, but acute hospitals’ share of the total provider profit pool will decline from 42% in 2019 to 39% by 2030. Capital is shifting aggressively to lower-cost outpatient settings: Ambulatory Surgery Center (ASC) EBITDA is forecast to grow at 6.7% annually (reaching 23.1% margins by 2030), compared to 3.7% annual growth for acute hospitals, driven by CMS expansion of the ASC Covered Procedures List and commercial payer site-of-care steerage.
- Pharmacy Supply Chain Re-Engineering: Total pharmacy value chain EBITDA is projected to expand from $97 billion in 2025 to $138 billion by 2030 (a 7% CAGR), with specialty pharmacy and clinical infusion capturing roughly half the pool. Hospital-owned specialty pharmacy represents the fastest-growing delivery segment, expanding at 15% annually. Simultaneously, legislative mandates—including PBM transparency provisions under the Consolidated Appropriations Act of 2026, successive Medicare drug price negotiations, and a revised 340B retrospective rebate pilot scheduled for 2027—are dismantling traditional hidden drug spreads and retrospective rebates in favor of transparent, fee-for-service administrative models.
Go to Source
2026-11-12 12:47
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.
